New-generation antibiotics and non-antibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers - PubMed
9 hours ago
- #Enterobacterales
- #metallo-β-lactamase
- #antibiotics
- New-generation antibiotics and non-antibiotic strategies are being developed to combat carbapenemase-producing Enterobacterales (CPE), with a focus on metallo-β-lactamase (MBL) producers.
- Cefiderocol showed lower susceptibility rates compared to aztreonam-avibactam against NDM-producing Enterobacterales.
- Novel β-lactamase inhibitors like taniborbactam (TAN), xeruborbactam (XER), zidebactam (ZID), and ANT2681 are active against MBLs.
- Nacubactam (NAC) combined with partner β-lactams is effective in vitro against CPE isolates with blaNDM genes.
- Combinations of TAN, XER, ZID, NAC, and ANT2681 with meropenem or cefepime are being developed for CPE treatment.
- XER paired with ceftibuten or tebipenem is under evaluation for treating infections caused by serine carbapenemase- and MBL-producing Enterobacterales.
- The novel monobactam LYS228 alone has shown good in vitro potency against MBL producers.
- Novel polymyxin derivatives (SPR741, SPR206, QPX9003) and bacteriophages exhibit promising activity against MBL-producing Enterobacterales.
- Continued monitoring of resistance trends and development of innovative therapeutic strategies are essential in combating CPE with blaMBL.